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ABSTRACT

Idiopathic CD4
+ T-cell lymphocytopenia (ICL) is a rare acquired T-cell immunodeficiency of unknown pathogenic basis. Six adults with ICL who developed opportunistic infections were investigated using extensive immunophenotyping analysis and functional evaluation of the chemokine receptor CXCR4. For all 6 patients studied, a profound defect in CXCR4
expression was detected at the surface of CD4 + T lymphocytes, in association with an abnormal intracellular accumulation of CXCR4 and of its natural ligand, the chemokine CXCL12. For all patients studied, CD4 + T-cell chemotactic response towards CXCL12 was decreased, while sensitivity to CXCL8 was preserved. CXCR4 recovery following ligandinduced endocytosis was impaired in ICL CD4 + T-cells. Upon in vitro addition of IL-2, membrane expression of CXCR4 returned to normal levels in 5/6 patients, while intracellular accumulation of CXCR4 and CXCL12 disappeared. Upon therapeutic administration of IL-2, CD4 + T-cell count and membrane CXCR4 expression and function improved over time in three of four patients treated. Therefore, our data indicate that ICL is associated with defective surface expression of CXCR4, which may be reversed by IL-2.
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INTRODUCTION
Idiopathic CD4
+ T-cell lymphocytopenia (ICL) is characterized by a profound and persistent CD4 + T-cell defect which predisposes to opportunistic infections [1] [2] [3] [4] [5] . ICL definition includes an absolute CD4 + T-cell count <300 cells/mm 3 or <20% of CD4 + T-cells on more than one occasion at least 6 weeks apart, together with lack of other known immune defects 6 . There is no clear evidence for an infectious or environmental cause of the disease 3, 7 . Heterogeneous immunologic profiles have been reported so far in ICL patients 1, 8, 9 . Interleukin-2 (IL-2) has been reported to increase CD4 + T-lymphocyte count and improve the outcome in a few ICL patients 10, 11 .
Mechanistic studies of T-cell function in ICL remain scarce. Decreased T-cell responses as well as increased T-cell activation have been reported 7, 12 . CD8 + T-cell counts remain in the normal range or are often decreased in ICL 13 . Functional investigations have revealed an increased propensity of ICL T-cells to undergo apoptosis, a process partially dependent on Fas expression 14, 15 . Markers for activation and turnover are increased in CD4 + T-cells but not in CD8 + T-cells, pointing at a specific alteration of the CD4 + T-cell compartment 13 . Another factor that may contribute to the CD4 + T-cell defect is a decreased clonogenic capacity of the bone marrow (BM) in ICL patients 16 . A frequent alteration observed in ICL consists in increased levels of IL-7 in peripheral blood, consistent with the triggering of a homeostatic response to restore normal CD4 + T-cell counts 9, 17 .
Chemokines are secreted proteins that govern the migration of leukocyte subsets to their specific niches within lymphoid organs and inflammatory sites 18, 19 . Chemokines mediate their functions by binding to chemokine receptors, which belong to the heptahelical G protein-coupled receptor (GPCR) family 20 . The chemokine Stromal cell-Derived Factor-1
(SDF-1/CXCL12), the sole natural ligand for the broadly expressed GPCR CXCR4, acts as a chemoattractant for hematopoietic progenitor cells (HPCs) and leukocytes (reviewed in 21 ).
For personal use only. on April 12, 2017 . by guest www.bloodjournal.org From CXCL12 is constitutively produced by stromal, epithelial and endothelial cells, notably in lymphoid organs. In postnatal life, CXCL12/CXCR4 interactions regulate the BM homing and retention of HPCs, the trans-endothelial migration of leukocytes, as well as their lymphoid and peripheral trafficking [22] [23] [24] [25] . In the thymus, CXCL12 expression by epithelial cells is required for the settling, survival/expansion and subsequent differentiation of CXCR4 + early T-lymphoid progenitors (reviewed in
). In the periphery, the CXCL12/CXCR4 axis contributes to the homing, positioning and activation of T-cells within secondary lymphoid tissues (reviewed in 27, 28 
PATIENTS AND METHODS
Subjects
Six adult patients were referred to us for investigation of a first opportunistic infection occurring in the setting of CD4 + T-cell counts persistently <300/mm 3 ( Table 1 
Sample processing and cell culture
Blood samples were drawn several months after effective cure to investigate the immune defect and the molecular basis of ICL. All experiments were performed within 3 hours following blood sampling. Samples from healthy controls were processed in parallel. PBMC were isolated from heparin-treated blood samples using Ficoll-Paque TM Plus (Amersham Biosciences, Uppsala, Sweden) density gradient centrifugation. Whole blood and PBMC were
For personal use only. on April 12, 2017 . by guest www.bloodjournal.org From used either right after collection or after overnight incubation at 37°C with 9% CO 2 in RPMI 1640 culture medium supplemented with 10% heat-inactivated human AB serum (Valbiotech, France) or FCS in the presence or absence of recombinant IL-2 (10 UI/ml, Peprotech Inc., NJ, USA). Because of a complex experimental design (patients living in remote areas requesting to combine outpatient visit, sampling and experiments), the number and identity of the patients varied for some of the analyses (specified in the corresponding sections).
Immunophenotypic analyses
Absolute counts were determined by four-color flow cytometry analyses (EPICS-XL MCL flow cytometer, Coulter Electronics Inc., Hialeah, FL) on whole blood samples with fluorescent beads used as an internal standard 33 . Seven Ab combinations were used for analysis of leukocyte subsets: 1. CD45-FITC, CD3-PECy5, CD4-RD1, CD8-ECD; 2. CD4-ECD, CD8-PECy5, CD38-RD1, HLA-DR-FITC; 3. CD4-ECD, CD8-PECy5, CD25-RD1, CD28-FITC; 4. CD4-ECD, CD8-PECy5, CD62L-RD1, CD45RA-FITC; 5. CD19-ECD, CD8-PECy5, CD56-RD1, CD16-FITC; 6. CD4-ECD, CD8-PECy5, CXCR4-PE, CCR5-FITC; 7.
CD3-ECD, CD8-PECy5, TCRαβ-RD1, TCRγδ-FITC. All monoclonal Abs (mAbs) were from Beckman Coulter except those specific for CXCR4 (clone 12G5) or CCR5 (clone 2D7) (BD Biosciences, San Diego, CA). Naive T-cells were defined by the co-expression of CD45RA and CD62L markers. Cells not co-expressing CD45RA and CD62L markers were considered as memory T-cells and those expressing CD38 and/or HLA-DR as activated Tcells.
Intracellular staining was performed in PBMC to detect CXCR4, CCR5 or CXCL12.
After incubation for 30 min with saturating amounts of non-conjugated Abs against CXCR4 and CCR5, cells were washed twice in PBS, fixed with 2% formaldehyde solution, and then treated for 10 min at 25°C with a permeabilization buffer (0.5% saponin, 5% FCS in PBS). 
Cytokine secretion assay
IFN-γ and TNF-α secretion were measured in PBMC-derived supernatants after 36 hours of culture in the presence of SEB, TT, candidin, PPD or MANO. Cytokines were detected by flow cytometry using the CBA technique (BD Biosciences). All analyses were performed with the Statistica 8.0 software, using the Mann-Whitney U nonparametric statistical test.
Significant differences between groups (p<0.05) were reported on data plots.
Chemotaxis assays
Chemotaxis was performed using 24-well chemotaxis chambers with polycarbonate filters (3 µm pore size) as described 35 
RESULTS
Immunological features of patients with ICL
All patients presented with CD4 + T-cell lymphocytopenia, an increase in NK-and γδT-cell populations, and a decrease in B-cell population which reached undetectable levels for 2 patients (P1 and P3) ( Table 1) . For all patients, serum levels of IgG, IgM and IgA were within the normal range (Table 1) . Of note, CD4 + T-cell depletion has persisted for over 18 months These findings provide evidence for severely compromised T-cell responses but normal immunoglobulin production in ICL patients.
Abnormal CXCR4 and CXCL12 detection in ICL CD4 + T-cells
Membrane CXCR4 expression was analyzed in whole blood samples. For all patients, CD4 + T-cell lymphocytopenia ( Figure 2A ) was associated with a profound decrease in CXCR4 expression at the surface of CD4 + T-cells (5.7±3.6% vs 25.0±5.0% in controls, p<0.0001) and CD8 + T-cells (6.4±3.8 vs 19.0±8.0% in controls, p<0.0001) ( Table 1 and Figure 2B ). Of note, CXCR4 down-regulation was more pronounced within the CD4 + than the CD8 + T-cell subset.
Membrane CXCR4 expression was found to be markedly decreased in both naive and memory CD4 + and CD8 + T-cell subsets (Supplemental Figure S1 ). In contrast, CXCR4
expression was preserved at the surface of monocytes (data not shown), suggesting a T-cellspecific defect. We found that lack of CXCR4 expression was not due to masking by a ligand, as cell washing in acidic glycine buffer (pH=2.7) did not change CXCR4 expression levels (data not shown). Expression levels of CCR5 in ICL CD4 + and CD8+ T-cells were in the normal range or even increased (Table 1 , Figure 2B , and supplemental Figure S1 ), indicating a CXCR4-specific rather than a global chemokine receptor defect. After overnight incubation with recombinant IL-2, expression levels of CXCR4 at the surface of CD4 + T-cells from 5 out of 6 patients were similar to those detected in control cells ( Figure 2B ). For the last patient (P3), CXCR4 remained barely detectable at the CD4 + T-cell surface after in vitro IL-2 treatment.
Loss of membrane CXCR4 expression was accompanied by an abnormal intracellular accumulation of CXCR4 (41.8±11.3% vs 2.0±0.6%, p<0.0001) and of CXCL12 (39.0±15.9%
vs 0%, p<0.0001) in CD4 + T-cells from all patients (Table 1 and Figure 2C ). In addition, an abnormal intracellular detection of CXCR4 was found in both naive and memory CD4 + and CD8 + T-cell subsets (Table 1 and Supplemental Figure S1 ). IL-2 therapy was initiated in 4 patients. At the end of the first IL-2 course, surface expression levels of CXCR4 were increased in CD4 + T-cells from 3 patients, namely P1, P2 and P6 ( Figure 2B ). Membrane recovery of CXCR4 was associated with a disappearance of intracellular CXCL12 ( Figure   2C ) and CXCR4 (data not shown). For P3, membrane expression of CXCR4 remained low following in vivo IL-2 administration, as it had after in vitro IL-2 stimulation (data not shown).
Lack of modulating effects of ICL plasmas on membrane CXCR4 expression
To gain insight into the mechanism underlying the abnormal intracellular accumulation of CXCR4 in ICL T-cells, CXCL12 levels were measured in plasmas from healthy and ICL (P1 and P6) subjects by immunoassay. No differences were found between patients and controls (data not shown). As polymorphisms in CXCR4 and CXCL12 genes have been associated with pathological disorders (reviewed in The levels of 25 analytes measured in P6 were in general within the range of values found in 11 healthy donors (Supplemental Table 1 ). We also investigated whether the plasma of ICL patients could induce CXCR4 down-regulation in normal PBMC. Membrane CXCR4 expression was measured in healthy donor PBMC incubated overnight with 30% plasma from ICL or heterologous healthy subjects. We did not detect a major difference between the effects of plasmas from 2 ICL patients (P1 and P6) and 4 healthy donors (Supplemental Figure S2 ). Overall, we have not identified so far a component of ICL plasmas that could account for CXCR4 down-regulation. courses of IL-2 administration are reported for P1 in Figure 5 and for all the 4 treated patients in Table 1 . A progressive increase in total lymphocyte number, ascribed to an increase in and reappearance of cryptococcal antigen in serum after sustained negativation for 48 months. 
IL-2 courses (data not shown). It is noteworthy that P3 was the patient for which CXCR4 expression did not improve after in vitro addition of IL-2. These findings suggest an association between the capacity of IL-2 to restore membrane CXCR4 expression and its therapeutic effect on CD4 + T-cell homeostasis.
DISCUSSION
In the present study, we provide a novel insight into ICL pathogenesis based on the systematic investigation of six patients. We show that ICL, at least in all the patients included in our study, is associated with a profound defect of membrane CXCR4 expression in circulating naive and memory CD4 + T-cells, accompanied by an abnormal intracellular accumulation of CXCR4 and of its ligand CXCL12. We did not find evidence for mutations, increased plasma concentration of CXCL12, or changes in cytokine levels in ICL plasmas that could account for CXCR4 down-regulation. This defect seemed to be specific for CXCR4, since expression levels of CCR5 remained within the normal range or was increased depending on the patient. Reduced levels of membrane CXCR4 expression were associated with impaired chemotactic responses to CXCL12, but not to CXCL8, another α-chemokine. 12 , provide a rationale for furthering cytokine-based immunotherapy in ICL patients. In conclusion, our data indicate that ICL is associated with a defect in membrane CXCR4 expression, which may be reversed by IL-2.
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